We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients S Lambert-Niclot et al. Atazanavir inhibitory quotient in first-line therapy
- Authors
Lambert-Niclot, S.; Machouf, N.; Peytavin, G.; Soulie, C.; Wirden, M.; Simon, A.; Murphy, R. L.; Katlama, C.; Thomas, R.; Calvez, V.; Marcelin, A.-G.
- Abstract
Objectives Studies have shown the importance of having a high protein-binding-adjusted inhibitory quotient (IQ) for protease inhibitors (PIs) boosted with ritonavir. The objective of this study was to explore the virological response when combination atazanavir/ritonavir was administered to treatment-naïve patients. Methods Protein-binding-adjusted IQs were calculated in 100 treatment-naïve patients initiating therapy with atazanavir 300 mg/ritonavir 100mg plus two nucleoside reverse transcriptase inhibitors. Results The median atazanavir trough level was 635 ng/mL [interquartile range (IQR) 342-1000] and the median atazanavir protein-binding-adjusted IQ was 45 (IQR 24-71). Eighty-four per cent of patients had a successful virological response, and those who failed did not develop resistance. The IQ for boosted atazanavir is high, resulting in rare treatment failure without resistance mutations. Conclusions This study showed that the protein-binding-adjusted IQ of atazanavir is close to those measured for lopinavir and darunavir used once daily in first-line treatment. Finally the selection of resistance in the case of virological failure (plasma viral load >4400 HIV-1 RNA copies/mL) to atazanavir/ ritonavir used in first-line therapy seems uncommon, as it is for all boosted PIs.
- Subjects
THERAPEUTIC use of protease inhibitors; ANTIVIRAL agents; COMBINATION drug therapy; COMPUTER software; HIV infections; NONPARAMETRIC statistics; HEALTH outcome assessment; U-statistics; LOGISTIC regression analysis; DATA analysis; PROTEASE inhibitors; VIRAL load; TREATMENT effectiveness; RETROSPECTIVE studies; DRUG administration; DRUG dosage; PHARMACOKINETICS; DRUG therapy
- Publication
HIV Medicine, 2010, Vol 11, Issue 10, p666
- ISSN
1464-2662
- Publication type
Article
- DOI
10.1111/j.1468-1293.2010.00839.x